The breadth of data being presented at the
premier radiology meeting of 2024 illustrates the increasing
relevance of portable, ultra-low-field MR brain imaging.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health
technology company that has redefined brain imaging with the first
FDA-cleared portable magnetic resonance (MR) brain imaging
system—the Swoop® system—today announced that ten scientific
abstracts highlighting ultra-low-field imaging will be presented at
the Radiological Society of North America (RSNA) 2024 Annual
Meeting in Chicago. For Hyperfine, this marks the largest number of
presentations at RSNA to date, underscoring the growing interest in
and expanding applications of the Swoop® system across varied
professional healthcare environments.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241119768356/en/
The Swoop® Portable MR Imaging® System
(Photo: Business Wire)
“We’re excited by the scientific community’s remarkable
enthusiasm for the Swoop® system,” said Dr. Edmond Knopp, Hyperfine
Chief Medical Officer. “Watching our technology propel real-world
applications across such diverse settings is a significant
milestone for Hyperfine. We look forward to continued momentum with
clinical evidence on the use of portable brain MRI and how it can
transform brain imaging and enhance patient care.”
The ten abstracts highlight a broad range of clinical and
technical applications across multiple sites of care, showcasing
the Swoop® system’s versatility in supporting patient management.
Clinical research to be presented spans workflow in both the
emergency department and neuro ICU and covers clinician experience
in intracerebral hemorrhage monitoring, acute ischemic stroke
detection, and advanced imaging techniques for multiple
sclerosis.
For more information about the Swoop® Portable MR Imaging®
system, please visit hyperfine.io.
Conference attendees can learn more during the presentations
listed below.
Name: Acute stroke detection using portable ultra
low-field MRI: A multicenter outlook Presented by: Nandor
Kolos Pinter, MD Session: Neuroradiology (Stroke: Diagnosis
and Treatment) | M3-SSNR04 Date and time: Monday, December
2, 9:30–10:30 AM Location: S406B
Name: Low-field (64mT) portable brain MRI in hospitalized
and emergency department patients: Real-world experience from our
first two years Presented by: Vinu Mathew, MD
Session: Science Session (Low-Field and Mobile MRI) |
T2-STCE1 Date and time: Tuesday, December 3, 9:00–9:30 AM
Location: Learning Center Theater 1
Name: Application of clinical low field mobile MRI in a
large academic medical center Presented by: Farzaneh
Rahmani, MD, MPH Session: Science Session (Low-Field and
Mobile MRI) | R2-STCE1 Date and time: Thursday, December 5,
9:00–9:30 AM Location: Learning Center Theater 1
Name: Utility of low-field portable brain MRI for ruling
out space-occupying lesions and hydrocephalus in patients with
papilledema and other ophthalmologic signs of possible increased
intracranial pressure: Preliminary experience Presented by:
Timothy Reynold Uy Lim, MD Session: Science Session
(Low-Field and Mobile MRI) | M3-STCE2 Date and time: Monday,
December 2, 10:00–10:30 AM Location: Learning Center Theater
2
Name: Efficacy of follow-up portable MRI compared to
standard follow-up head CT for interval evaluation of traumatic
intracranial hemorrhage Presented by: Lauren Thompson
Session: Science Session (Low-Field and Mobile MRI) |
T6-STCE2 Date and time: Tuesday, December 3, 1:30–2:00 PM
Location: Learning Center Theater 2
Name: A deep learning framework for generating synthetic
low-field imaging with paired high and low-field data Presented
by: Alfredo Lucas, MS, BS Session: Science Session
(Low-Field and Mobile MRI) | R2-STCE1 Date and time:
Thursday, December 5, 9:00–9:30 AM Location: Learning Center
Theater 1
Name: Quantifying brain volumes and lesion burden in
relation to disease duration and severity in multiple sclerosis
with low-field MRI Presented by: Alfredo Lucas, MS, BS
Session: Science Session (Low-Field and Mobile MRI) |
S1-STCE1 Date and time: Sunday, December 1, 9:30–10:00 AM
Location: Learning Center Theater 1
Name: Detecting myelin loss at 0.064T using a novel
myelin water imaging technique: A multiple sclerosis case study
Presented by: Shannon H. Kolind, PhD Session: Science
Session (Low-Field and Mobile MRI) | M7-STCE1 Date and time:
Monday, December 2, 2:30–3:00 PM Location: Learning Center
Theater 1
Name: Implementation and reproducibility assessment of
myelin-sensitive scans with mobile ultra-low field MRI Presented
by: Sharada Balaji Session: Science Session (Low-Field
and Mobile MRI) | R2-STCE1 Date and time: Thursday, December
5, 9:00–9:30 AM Location: Learning Center Theater 1
Name: Initial experience with low-field point-of-care MRI
in animal stroke models Presented by: Nandor Kolos Pinter,
MD Session: Neuroradiology Wednesday Afternoon Poster
Discussions I | W5A-SPNR Date and time: Wednesday, December
4, 12:15–12:45 PM Location: Learning Center (Poster
Session)
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is U.S. Food and Drug
Administration (FDA) cleared for brain imaging of patients of all
ages. It is a portable, ultra-low-field magnetic resonance imaging
device for producing images that display the internal structure of
the head where full diagnostic examination is not clinically
practical. When interpreted by a trained physician, these images
provide information that can be useful in determining a diagnosis.
The Swoop® system also has CE certification in the European Union
and UKCA certification in the United Kingdom. The Swoop® system is
commercially available in a select number of international
markets.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health
technology company that has redefined brain imaging with the Swoop®
system—the first FDA-cleared, portable, ultra-low-field, magnetic
resonance brain imaging system capable of providing imaging at
multiple points of professional care. The mission of Hyperfine,
Inc. is to revolutionize patient care globally through
transformational, accessible, clinically relevant diagnostic
imaging. Founded by Dr. Jonathan Rothberg in a technology-based
incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers,
and physicists developed the Swoop® system out of a passion for
redefining brain imaging methodology and how clinicians can apply
accessible diagnostic imaging to patient care. For more
information, visit hyperfine.io.
The Hyperfine logo, Swoop, and Portable MR Imaging are
registered trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Actual results of
Hyperfine, Inc. (the “Company”) may differ from its expectations,
estimates and projections and consequently, you should not rely on
these forward-looking statements as predictions of future events.
Words such as “expect,” “estimate,” “project,” “budget,”
“forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue,” and
similar expressions (or the negative versions of such words or
expressions) are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, the Company’s goals and commercial plans, the benefits
of the Company’s products and services, and the Company’s future
performance and its ability to implement its strategy. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the Company’s control and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: the success, cost and timing of the Company’s product
development and commercialization activities, including the degree
that the Swoop® system is accepted and used by healthcare
professionals; the impact of COVID-19 on the Company’s business;
the inability to maintain the listing of the Company’s Class A
common stock on the Nasdaq; the Company’s inability to grow and
manage growth profitably and retain its key employees; changes in
applicable laws or regulations; the inability of the Company to
raise financing in the future; the inability of the Company to
obtain and maintain regulatory clearance or approval for its
products, and any related restrictions and limitations of any
cleared or approved product; the inability of the Company to
identify, in-license or acquire additional technology; the
inability of the Company to maintain its existing or future
license, manufacturing, supply and distribution agreements and to
obtain adequate supply of its products; the inability of the
Company to compete with other companies currently marketing or
engaged in the development of products and services that the
Company is currently marketing or developing; the size and growth
potential of the markets for the Company’s products and services,
and its ability to serve those markets, either alone or in
partnership with others; the pricing of the Company’s products and
services and reimbursement for medical procedures conducted using
the Company’s products and services; the Company’s estimates
regarding expenses, revenue, capital requirements and needs for
additional financing; the Company’s financial performance; and
other risks and uncertainties indicated from time to time in
Company’s filings with the Securities and Exchange Commission,
including those under “Risk Factors” therein. The Company cautions
readers that the foregoing list of factors is not exclusive and
that readers should not place undue reliance upon any
forward-looking statements, which speak only as of the date made.
The Company does not undertake or accept any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions or circumstances
on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241119768356/en/
Media Contact Dana Schroeder Health+Commerce
dana@healthandcommerce.com
Investor Contact Marissa Bych Gilmartin Group LLC
marissa@gilmartinir.com
Hyperfine (NASDAQ:HYPR)
過去 株価チャート
から 11 2024 まで 12 2024
Hyperfine (NASDAQ:HYPR)
過去 株価チャート
から 12 2023 まで 12 2024
